SCHEMBL6779571

SCHEMBL6779571

NN=CNc1cccc(C(=O)NCC(=O)NC(Cc2ccc(Br)cc2)C(=O)O)c1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 2/20 0.43
ITGB1 P05556 10/20 0.42
ITGB3 P05106 9/20 0.42
ITGAV P06756 9/20 0.42
ITGA2B P08514 5/20 0.42
ITGB5 P18084 5/20 0.42
GPR132 Q9UNW8 1/20 0.41
ITGA5 P08648 4/20 0.41
MDM2 Q00987 3/20 0.41
ITGA4 P13612 1/20 0.40
ACE P12821 2/20 0.39
SENP1 Q9P0U3 2/20 0.39
MDM4 O15151 2/20 0.39
NPC1 O15118 1/20 0.39
GAA P10253 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6775970 0.92 GPR132 (0.49) ITGB1ITGB3ITGAVITGA2BITGB5
SCHEMBL6773776 0.91 CTSB (0.43) FPR2ITGB1ITGB3ITGAVGPR132
SCHEMBL7823171 0.91 ITGB3 (0.50) ITGB1ITGB3ITGAVITGA2BITGB5
SCHEMBL7340124 0.90 CA2 (0.46) ITGB1ITGB3ITGAVITGA2BITGB5
SCHEMBL7345088 0.89 ITGB3 (0.41) ITGB1ITGB3ITGAVITGA2BITGB5
SCHEMBL7340345 0.88 TP53 (0.39) ITGB1ITGB3ITGAVITGA5MDM2
SCHEMBL7837213 0.88 CTSL (0.41) ITGB1ITGB3ITGAVGPR132ITGA5
SCHEMBL3051751 0.87 GPR139 (0.44) ITGB1ITGB3ITGAVITGB5GPR132
SCHEMBL7345869 0.87 HTT (0.43) ITGB1ITGB3ITGAVITGB5ITGA5
SCHEMBL6778084 0.87 GPR139 (0.45) FPR2ITGB1ITGB3ITGAVITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed